IN2015MN00002A - - Google Patents
Info
- Publication number
- IN2015MN00002A IN2015MN00002A IN2MUN2015A IN2015MN00002A IN 2015MN00002 A IN2015MN00002 A IN 2015MN00002A IN 2MUN2015 A IN2MUN2015 A IN 2MUN2015A IN 2015MN00002 A IN2015MN00002 A IN 2015MN00002A
- Authority
- IN
- India
- Prior art keywords
- stereoisomer
- amenable
- disorders
- inhibiting
- prevention
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 abstract 1
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 abstract 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2MUN2015 IN2015MN00002A (OSRAM) | 2012-07-09 | 2013-07-09 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN762KO2012 | 2012-07-09 | ||
| PCT/IB2013/055618 WO2014009872A1 (en) | 2012-07-09 | 2013-07-09 | Tetrahydroquinazolinone derivatives as parp inhibitors |
| IN2MUN2015 IN2015MN00002A (OSRAM) | 2012-07-09 | 2013-07-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015MN00002A true IN2015MN00002A (OSRAM) | 2015-10-16 |
Family
ID=48906465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2MUN2015 IN2015MN00002A (OSRAM) | 2012-07-09 | 2013-07-09 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9359367B2 (OSRAM) |
| EP (1) | EP2870140B8 (OSRAM) |
| AU (1) | AU2013288265B2 (OSRAM) |
| CA (1) | CA2877826C (OSRAM) |
| ES (1) | ES2595240T3 (OSRAM) |
| IN (1) | IN2015MN00002A (OSRAM) |
| WO (1) | WO2014009872A1 (OSRAM) |
| ZA (1) | ZA201409497B (OSRAM) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101921486B1 (ko) | 2014-04-10 | 2018-11-26 | 후베이 바이오-파마슈티컬 인더스트리얼 테크놀로지컬 인스티튜트 인크. | ＰＡＲＰ억제제인 4Ｈ-피라졸로[1,5-ａ]벤즈이미다졸 화합물의 아날로그 |
| WO2016012956A1 (en) * | 2014-07-24 | 2016-01-28 | Lupin Limited | Isoquinolinone derivatives as parp inhibitors |
| WO2017013593A1 (en) | 2015-07-22 | 2017-01-26 | Lupin Limited | Isoquinolinone derivatives as parp inhibitors |
| AU2016308717A1 (en) * | 2015-08-17 | 2018-01-25 | Lupin Limited | Heteroaryl derivatives as PARP inhibitors |
| CN108727391A (zh) * | 2017-04-21 | 2018-11-02 | 上海迪诺医药科技有限公司 | Parp抑制剂化合物非晶形及其制备方法和应用 |
| EP3728207B1 (en) | 2017-12-21 | 2023-02-01 | Ribon Therapeutics Inc. | Quinazolinones as parp14 inhibitors |
| CN111269216A (zh) * | 2018-12-05 | 2020-06-12 | 中国医学科学院药物研究所 | 含有哌嗪酮的喹唑啉二酮盐类化合物、其制备方法、药物组合物和用途 |
| WO2021041573A2 (en) * | 2019-08-27 | 2021-03-04 | The Johns Hopkins University | Biomarkers for neurodegenerative disorders |
| TWI749881B (zh) * | 2019-11-21 | 2021-12-11 | 大陸商深圳信立泰藥業股份有限公司 | 二氧代哌類衍生物、其製備方法及其在醫藥上的應用 |
| CN112608303B (zh) * | 2020-12-25 | 2021-10-26 | 华南理工大学 | 一种哌嗪类中间体及其制备方法与应用 |
| CN114044769B (zh) * | 2021-11-25 | 2023-12-12 | 中山大学 | 一种β-吲哚喹唑啉酮衍生物及其制备方法和应用 |
| GB2634233A (en) * | 2023-10-02 | 2025-04-09 | Duke Street Bio Ltd | PARP1 inhibitor compounds |
| WO2025091346A1 (en) * | 2023-11-01 | 2025-05-08 | Suzhou Eoc Medical Research Co., Ltd. | Parp inhibitors and uses thereof |
| WO2025101854A1 (en) * | 2023-11-09 | 2025-05-15 | University Of Kentucky Research Foundation | Opioid compounds |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2027645A1 (de) | 1970-06-05 | 1971-12-09 | Byk Gulden Lomberg Chemische Fa bnk GmbH, 7750 Konstanz | Piperazinylalkyl chinazolon (4) den vate, Verfahren zu deren Herstellung und sie enthaltende Arzneimittel |
| BE503170A (OSRAM) | 1975-09-02 | |||
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| IL90858A (en) | 1988-07-07 | 1994-08-26 | Rhone Poulenc Sante | Derivatives of (AZA) naphthalensultam, their preparation and compositions containing them |
| DE4312832C1 (de) | 1993-04-20 | 1994-10-20 | Boehringer Ingelheim Kg | Verfahren zur Herstellung enantiomerenreiner Ketale der (S)- und (R)-3-Oxocyclopentancarbonsäure |
| DE4316576A1 (de) | 1993-05-18 | 1994-11-24 | Boehringer Ingelheim Kg | Verbessertes Verfahren zur Herstellung von 1,3-Dipropyl-8-(3-Oxocyclopentyl)-xanthin |
| US5589489A (en) | 1993-12-15 | 1996-12-31 | Zeneca Limited | Cyclic amide derivatives for treating asthma |
| GB9904275D0 (en) | 1999-02-24 | 1999-04-21 | Cancer Res Campaign Tech | Anti-cancer compounds |
| WO2001070737A2 (en) | 2000-03-20 | 2001-09-27 | Sepracor, Inc. | Therapeutic heterocyclic compounds for the treatment of asthma and allergy and use thereof |
| DK1178047T3 (da) | 2000-08-03 | 2004-05-24 | Pfizer Prod Inc | Diazabicyclooctanderivater og terapeutiske anvendelser deraf |
| AUPR201600A0 (en) | 2000-12-11 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivative |
| WO2002094790A1 (en) * | 2001-05-23 | 2002-11-28 | Mitsubishi Pharma Corporation | Fused heterocyclic compound and medicinal use thereof |
| NZ530646A (en) | 2001-07-11 | 2008-01-31 | Upjohn Co | N-(3-amino-2-hydroxy-propyl) substituted alkylamide compounds |
| AUPR975601A0 (en) | 2001-12-24 | 2002-01-31 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivatives |
| AUPS019702A0 (en) | 2002-01-29 | 2002-02-21 | Fujisawa Pharmaceutical Co., Ltd. | Condensed heterocyclic compounds |
| EP1539180A4 (en) | 2002-08-21 | 2006-08-30 | Cytokinetics Inc | COMPOUNDS, COMPOSITIONS AND METHODS |
| GB0317466D0 (en) | 2003-07-25 | 2003-08-27 | Univ Sheffield | Use |
| CN1266155C (zh) | 2003-08-01 | 2006-07-26 | 浙江震元制药有限公司 | 6－氯－4－羟基－2－甲基－2H－噻吩并（2，3－e）－1，2－噻嗪－1，1－二氧化物－3－羧酸酯的合成方法 |
| JP5043429B2 (ja) | 2003-08-18 | 2012-10-10 | ハー・ルンドベック・アクチエゼルスカベット | トランス−４−（（１ｒ，３ｓ）−６−クロロ−３−フェニルインダン−１−イル）−１，２，２−トリメチルピペラジンのコハク酸塩およびマロン酸塩、および薬剤としての使用方法 |
| US20050065178A1 (en) | 2003-09-19 | 2005-03-24 | Anwer Basha | Substituted diazabicycloakane derivatives |
| KR20060123403A (ko) | 2003-12-01 | 2006-12-01 | 쿠도스 파마슈티칼스 리미티드 | 암 치료를 위한 ｄｎａ 손상 수복 억제제 |
| US9016221B2 (en) | 2004-02-17 | 2015-04-28 | University Of Florida Research Foundation, Inc. | Surface topographies for non-toxic bioadhesion control |
| JP4912145B2 (ja) | 2004-02-26 | 2012-04-11 | あすか製薬株式会社 | ピリミジン誘導体 |
| US7381822B2 (en) | 2004-03-31 | 2008-06-03 | The General Hospital Corporation | Diagnostic and therapeutic alkyl piperidine/piperazine compounds and process |
| US20050245534A1 (en) | 2004-04-29 | 2005-11-03 | Link James T | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme |
| KR20070008709A (ko) | 2004-04-30 | 2007-01-17 | 다케다 야쿠힌 고교 가부시키가이샤 | 이종환식 아미드 화합물 및 이의 ｍｍｐ-13 저해제로서의용도 |
| AU2005259192C1 (en) | 2004-06-30 | 2012-03-01 | Janssen Pharmaceutica N.V. | Substituted 2-alkyl quinazolinone derivatives as PARP inhibitors |
| US20060079510A1 (en) | 2004-09-30 | 2006-04-13 | Kristoffer Hellstrand | Use of PARP-1 inhibitors for protecting tumorcidal lymphocytes from apoptosis |
| US20080076760A1 (en) | 2004-11-10 | 2008-03-27 | Wakamoto Pharmaceutical Co., Ltd | 2,3,4,5-tetrahydro-1h-1,5-benzodiazepine derivative and medicinal composition |
| BRPI0517426A (pt) | 2004-12-17 | 2008-10-07 | Astrazeneca Ab | composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, métodos para produzir um efeito anti-proliferação celular, para produzir um efeito inibitório de cdk2, e para tratar uma doença em um animal de sangue quente |
| CA2602474C (en) | 2005-03-23 | 2014-06-10 | Actelion Pharmaceuticals Ltd | Hydrogenated benzo (c) thiophene derivatives as immunomodulators |
| WO2006137510A1 (ja) | 2005-06-24 | 2006-12-28 | Ono Pharmaceutical Co., Ltd. | 脳血管障害時における出血低減剤 |
| US7300947B2 (en) | 2005-07-13 | 2007-11-27 | Banyu Pharmaceutical Co., Ltd. | N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives |
| CA2615380A1 (en) | 2005-07-15 | 2007-01-25 | Schering Corporation | Quinazoline derivatives useful in cancer treatment |
| JP2009517403A (ja) | 2005-11-25 | 2009-04-30 | ユニバーシティー オブ メディシン アンド デンティストリー オブ ニュージャージー | Ｐａｒｐ−１阻害剤の使用 |
| CN101360738A (zh) | 2005-12-21 | 2009-02-04 | 佩因赛普托药物公司 | 调节门控离子通道的组合物和方法 |
| WO2007076055A2 (en) | 2005-12-22 | 2007-07-05 | Entremed, Inc. | Compositions and methods comprising proteinase activated receptor antagonists |
| EP2233472B1 (en) | 2006-03-28 | 2014-01-15 | Atir Holding S.A. | Heterocyclic compounds and uses thereof in the treatment of sexual disorders |
| BRPI0710943A2 (pt) | 2006-04-26 | 2012-06-26 | Genentech Inc | compostos farmacêuticos |
| WO2008080824A1 (en) | 2006-12-29 | 2008-07-10 | F. Hoffmann-La Roche Ag | Aromatic sulfonated ketals |
| EP2208728A4 (en) | 2007-09-19 | 2011-12-21 | Inst Med Molecular Design Inc | HETEROCYCLIC DERIVATIVE DERIVATIVE DERIVATIVE TO 11 -? - HYDROXYSTEROIDDEHYDROGENASE TYPE I |
| WO2009041566A1 (ja) | 2007-09-26 | 2009-04-02 | Santen Pharmaceutical Co., Ltd. | キナゾリノン誘導体又はキノキサリン誘導体を有効成分として含有する後眼部疾患の予防又は治療剤 |
| JP2009096804A (ja) | 2007-09-26 | 2009-05-07 | Santen Pharmaceut Co Ltd | キナゾリノン誘導体又はキノキサリン誘導体を有効成分として含む角結膜障害の予防又は治療剤 |
| WO2009086303A2 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| FR2926221A1 (fr) | 2008-01-14 | 2009-07-17 | Tassin Thomas | Compositions permettant la reproduction artificielle des conditions pharmacologiques de la dependance aux drogues addictives telles que opiaces, psychostimulants, tabac et alcool, par la combinaison de nicotine et d'un ligand. |
| WO2009114459A2 (en) | 2008-03-10 | 2009-09-17 | The Trustees Of The University Of Pennsylvania | Anti-neoplastic combination therapeutic regimen involving co-disruption of parp pathway and mre11/rad50/nbs1 complex and compositons useful therein |
| CN102232076B (zh) | 2008-12-05 | 2014-12-31 | 霍夫曼-拉罗奇有限公司 | 吡咯并吡嗪基脲激酶抑制剂 |
| WO2010082813A1 (en) | 2009-01-13 | 2010-07-22 | Academisch Medisch Centrum Bij De Universiteit Van Amsterdam | Method of treating cancer |
| WO2011119345A2 (en) | 2010-03-25 | 2011-09-29 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| CN103228141B (zh) | 2010-09-03 | 2016-04-20 | 拜耳知识产权有限责任公司 | 取代的稠合的嘧啶酮和二氢嘧啶酮 |
-
2013
- 2013-07-09 WO PCT/IB2013/055618 patent/WO2014009872A1/en not_active Ceased
- 2013-07-09 IN IN2MUN2015 patent/IN2015MN00002A/en unknown
- 2013-07-09 EP EP13742752.2A patent/EP2870140B8/en not_active Not-in-force
- 2013-07-09 CA CA2877826A patent/CA2877826C/en not_active Expired - Fee Related
- 2013-07-09 ES ES13742752.2T patent/ES2595240T3/es active Active
- 2013-07-09 AU AU2013288265A patent/AU2013288265B2/en not_active Ceased
- 2013-07-09 US US14/411,968 patent/US9359367B2/en not_active Expired - Fee Related
-
2014
- 2014-12-23 ZA ZA2014/09497A patent/ZA201409497B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201409497B (en) | 2015-12-23 |
| EP2870140A1 (en) | 2015-05-13 |
| CA2877826A1 (en) | 2014-01-16 |
| AU2013288265A1 (en) | 2015-01-29 |
| US20150152118A1 (en) | 2015-06-04 |
| ES2595240T3 (es) | 2016-12-28 |
| EP2870140B1 (en) | 2016-07-27 |
| WO2014009872A1 (en) | 2014-01-16 |
| CA2877826C (en) | 2016-08-16 |
| US9359367B2 (en) | 2016-06-07 |
| AU2013288265B2 (en) | 2017-04-06 |
| EP2870140B8 (en) | 2016-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015MN00002A (OSRAM) | ||
| PH12018500360A1 (en) | Heteroaryl derivatives as parp inhibitors | |
| PH12018500041A1 (en) | Substituted aza compoounds as irak-4 inhibitors | |
| PH12015501517A1 (en) | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease | |
| MX352672B (es) | Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer. | |
| PH12018500040A1 (en) | Indazole and azaindazole compounds as irak-4 inhibitors | |
| PH12016502382A1 (en) | Substituted indazole compounds as irak4 inhibitors | |
| SA515360469B1 (ar) | مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها | |
| MX2015011245A (es) | Un inhibidor de mdm2 derivado de acido benzoico para el tratamiento del cancer. | |
| MX2011009796A (es) | Inhibidores de la cinasa pi3. | |
| MY199894A (en) | Prmt5 inhibitors and uses thereof | |
| MY199131A (en) | Human plasma kallikrein inhibitors | |
| MD4659B1 (ro) | Polimorf al inhibitorilor SYK | |
| MX2014014106A (es) | Derivados de acido 7-oxo-tiazolopiridinocarbonico y su uso en el tratamiento, disminucion o prevencion de una enfermedad viral. | |
| MX2013012588A (es) | Inhibidores de cinasa. | |
| PH12017500007A1 (en) | Quinolizinone derivatives as p13k inhibitors | |
| MX2013011591A (es) | Métodos y composiciones para tratar enfermedades neurodegenerativas. | |
| WO2014155300A3 (en) | Substitued pyrimidine amine derivatives as tak-1 inhibitors | |
| MY184858A (en) | Substituted pyridopyrimidine compounds and their use as flt3 inhibitors | |
| MX2014003801A (es) | Derivados de pirimidin-4-ona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral. | |
| NZ706591A (en) | Oxazolidin-2-one-pyrimidine derivatives | |
| MX362896B (es) | Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cáncer. | |
| MX2015008288A (es) | Derivados de piridona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral. | |
| MY184561A (en) | Substituted pyrimidine compounds and their use as syk inhibitors | |
| MX2016004967A (es) | Tratamiento para cancer pancreatico. |